Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase EARLY_PHASE1 1Phase 1 1

Status

Suspended 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 10Lung Neoplasms 9Small Cell Lung Carcinoma 8Breast Neoplasms 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Melanoma 5Glioblastoma 5Carcinoma, Transitional Cell 5Ovarian Neoplasms 4Advanced Solid Tumor 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Liver Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Solid Cancer 2Small Cell Lung Cancer Extensive Stage 2Recurrence 2Neuroendocrine Tumors 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Gemcitabine 15pembrolizumab 13Doxorubicin 13Radiotherapy 12Docetaxel 9Nivolumab 8Filgrastim 7Cyclophosphamide 7pazopanib 6Ifosfamide 6130-nm albumin-bound paclitaxel 5Temozolomide 4Irinotecan 4Ipilimumab 4Imatinib Mesylate 4Albumin-Bound Paclitaxel 4talimogene laherparepvec 3surufatinib 3pegfilgrastim 3eribulin 3atezolizumab 3Vinorelbine 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3PM 01183 3Drug Therapy 3Cisplatin 3toripalimab 2spartalizumab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma × atezolizumab × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04216953 2026-04-23

COTESARC

Centre Leon Berard

Phase 1/2 Completed
229 enrolled
Sarcoma

Sarcoma

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡